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Abstract
Introduction of nucleos(t)ide analogues (NAs) for oral 
antiviral therapy has dramatically improved the clini-
cal outcome in patients with chronic hepatitis B (CHB). 
Although current international guidelines for the man-
agement of CHB provide information regarding when 
to begin the antiviral therapy with NAs, there is no 
clear consensus on when to stop the treatment, espe-
cially for those who respond to the therapy. Hepatitis 
B surface antigen loss has been regarded as an ideal 
endpoint of oral antiviral therapy with NAs, however 
since this is rarely achieved, practical endpoints have 
been suggested by the international guidelines. Despite 
the stopping rules recommended by the international 
guidelines, whether oral antiviral therapy with NAs can 
be safely discontinued is of major concern. While atten-
tion has been drawn to whether antiviral treatment with 
NAs can be a finite therapy, there is lack of sufficient 
data on off-treatment durability of highly potent NAs. 
Based on the available evidences, current guidelines for 
stopping NA therapy seems to be inadequate in terms 
of off-treatment durability, with relapse rates of more 
than 40% for both hepatitis Be antigen (HBeAg)-positive 
and HBeAg-negative patients. Therefore, further stud-
ies are required to accumulate data on off-treatment 
durability of highly potent NAs, and future studies are 
warranted to identify adequate predictive markers that 
could provide supplementary information to guide the 
timing of stopping NA therapy.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Introduction of nucleos(t)ide analogues (NAs) 
for oral antiviral therapy has dramatically improved 
the clinical outcome in patients with chronic hepatitis 
B (CHB). While attention has been drawn to whether 
antiviral treatment with NAs can be a finite therapy in 
patients with CHB, current guidelines for stopping NA 
therapy seems to be inadequate in terms of off-treat-
ment durability in both hepatitis Be antigen (HBeAg)-
positive and HBeAg-negative patients. In the present 
work, we discussed the validity of current stopping 
rules of NA therapy and addressed areas of uncertainty 
in deciding the best timing to stop NA treatment.
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people worldwide and is a major cause of  chronic liver 
disease, which may eventually evolve to cirrhosis and hepa-
tocellular carcinoma (HCC)[1,2]. There are several host and 
viral factors which affect the natural course of  HBV infec-
tion, and active HBV replication has been described as the 
key driving force for the subsequent HBV-related immune 
clearance that determine liver injury and progression of  
liver disease, implicating the importance of  sustained viral 
suppression, or ideally, elimination of  the virus[3].
In recent years, introduction of  nucleos(t)ide ana-
logues (NAs) for oral antiviral therapy has dramatically 
improved the clinical outcome in patients with chronic 
hepatitis B (CHB). Although current international guide-
lines for the management of  CHB provide information 
regarding when to begin the antiviral therapy with NAs, 
there is no clear consensus on when to stop the treat-
ment, especially for those who respond to the therapy.
In this article, we discuss the validity of  current stop-
ping rules of  NA therapy recommended by the interna-
tional guidelines by assessing the durability of  antiviral 
response after cessation of  NAs based on currently avail-
able literature. We also address areas of  uncertainty in 
deciding the best timing to stop NA therapy. 
TREATMENT GOALS AND STOPPING 
RULES
Seroclearance of  hepatitis B surface antigen (HBsAg) is a 
condition that is most similar to complete and definitive 
remission status of  chronic HBV infection. In this view, 
the international guidelines have suggested HBsAg loss 
as an ideal endpoint of  oral antiviral therapy with NAs. 
However, HBsAg loss is almost negligible even after a 
long-term therapy[4-7]. Therefore it is anticipated that most 
patients with CHB probably require lifelong oral antivi-
ral treatment with NAs. The primary goals of  antiviral 
therapy are sustained suppression of  HBV replication 
and hepatic inflammation thereby improving long-term 
outcomes and prolonging patient survival by preventing 
the development of  progressive fibrosis, cirrhosis and/or 
HCC[8-10]. Response to treatment is assessed based on 
biochemical, virological, serological, as well as histological 
parameters. Treatment with NAs can effectively suppress 
HBV replication and prevent the progression of  disease. 
On the other hand, long-term treatment with NAs is 
associated with significant problems in the management 
of  CHB. Generally, adherence to long-term therapy is 
an important issue in patient management, and safety 
of  long-term NA treatment is of  concern since they are 
primarily eliminated by the kidney[11]. Financial burden 
of  long-term NA treatment represent another important 
issue in the management of  CHB. In this regard, interna-
tional guidelines have suggested the timing of  stopping 
antiviral NAs based on the studies demonstrating off-
therapy durability of  responses to NA therapy in patients 
with CHB (Table 1). A finite therapy would not only 
offer reduced financial burden and increased treatment 
safety but also encourage the patients to stay adherent to 
the treatment.
For patients with hepatitis B e antigen (HBeAg)-
positive CHB, the European Association for the Study 
of  Liver (EASL) guideline recommends HBsAg loss with 
or without seroconversion as an ideal finite goal of  NA 
therapy[9]. However, NA therapy-induced HBsAg sero-
clearance or seroconversion is only achievable in a minor-
ity of  patients. Hence, the EASL guideline also provides 
a reasonable option that is comparable to the recommen-
dations of  the asian pacific association for the study of  
the liver (APASL) and american association of  the study 
of  liver disease (AASLD) guidelines. The APASL guide-
line suggests that treatment can be stopped after HBeAg 
seroconversion with undetectable HBV DNA by a sensi-
tive polymerase chain reaction assay for at least 12 mo[8]. 
Likewise, the EASL and AASLD guidelines recommend 
that treatment can be stopped after HBeAg seroconver-
sion with undetectable HBV DNA and an additional 6-12 
mo of  consolidation therapy[9,10]
For patients with HBeAg-negative CHB, however, 
currently there is no clear consensus on the optimal 
duration of  oral antiviral therapy with NAs. Both the 
EASL and AASLD guidelines recommend long-term NA 
therapy until HBsAg seroclearance has been achieved[9,10]. 
On the contrary, the APASL guideline suggests that un-
less HBsAg seroclearance has been achieved, cessation 
of  NA therapy can be considered after at least 2 years of  
treatment if  HBV DNA remains undetectable on three 
separate occasions 6 mo apart[8].
Despite the stopping rules recommended by the in-
ternational guidelines, whether oral antiviral therapy with 
NAs can be safely discontinued is of  major concern. 
Accordingly, many studies have been conducted to evalu-
ate the durability of  antiviral response after cessation of  
NAs in patients with CHB (Table 2).
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HBeAg-positive chronic 
hepatitis B
HBeAg-negative chronic 
hepatitis B
  APASL 2012 HBeAg seroconversion 
with undetectable HBV 
DNA for at least 12 mo
HBsAg seroclearance or
NA therapy > 2 yr and 
undetectable HBV DNA on 
three separate occasions, 6 mo 
apart
  EASL 2012 HBsAg seroclearance or
HBeAg seroconversion 
with undetectable HBV 
DNA and 12 mo of 
consolidation therapy
HBsAg seroclearance
  AASLD 2009 HBeAg seroconversion 
with undetectable HBV 
DNA and > 6 mo of 
consolidation therapy
HBsAg seroclearance
Table 1  Criteria for stopping nucleos(t)ide analogue therapy 
in chronic hepatitis B patients
HBeAg: Hepatitis Be antigen; APASL: Asian Pacific Association for the 
Study of the Liver; EASL: European Association for the Study of Liver; 
AASLD: American Association of the Study of Liver Disease.
OFF-THERAPY DURABILITY OF 
ANTIVIRAL RESPONSE
HBeAg-positive patients
Initial studies with lamivudine showed disappointing re-
sults with its antiviral durability after cessation of  therapy. 
Although a study of  39 patients reported lamivudine-
induced HBeAg seroconversion to be durable in 77% 
of  patients[12], a subsequent study of  34 HBeAg-positive 
CHB patients in whom lamivudine was stopped after 
HBeAg seroconversion showed that the cumulative re-
lapse rate was 37.5% after 1 year and increased to 49.2% 
after 2 years of  discontinuation[13]. Similarly, Chien et al[14] 
also reported that 48% of  the patients relapsed after dis-
continuing lamivudine for 12 mo. In parallel with these 
results, several studies from different groups showed 
that the off-treatment durability of  lamivudine-induced 
HBeAg seroconversion was not sustained in a large pro-
portion of  patients, with cumulative relapse rate of  more 
than 50% after 1 year[15-17].
On the other hand, some studies have reported a 
higher antiviral durability after cessation of  therapy. 
In a study of  61 patients, Ryu et al[18] reported that the 
cumulative relapse rate was 15% at 6 mo and 31% at 2 
years after stopping lamivudine therapy. A more recent 
study by Lee et al[19] also showed a durable off-treatment 
response in 178 patients with lamivudine-induced com-
plete response. In this study, the cumulative relapse rate 
was 15.9% at 1 year and 30.2% at 5 years. These results 
were supported by a more recent prospective study with 
82 patients demonstrating a cumulative relapse rate of  
23.4% at 6 mo and 29.4% at 4 years after discontinuation 
of  lamivudine[20]. 
However, in a series of  recent studies with various an-
tiviral NAs the off-treatment response was shown to be 
not durable despite consolidation therapy after HBeAg 
seroconversion. A study of  132 patients who achieved 
HBeAg seroconversion by various NAs demonstrated an 
overall relapse rate of  67% despite consolidation therapy 
after HBeAg seroconversion[21]. Moreover, a more recent 
study of  39 patients treated with various NAs reported 
that almost all (90%) patients who stopped NA therapy 
after achieving HBeAg seroconversion and clinical re-
sponse experienced recurrent viremia despite consolida-
tion therapy prior to discontinuation of  NAs[22].
To summarize, the results from these studies imply 
that the current guidelines of  stopping NAs after achiev-
ing HBeAg seroconversion with undetectable HBV 
DNA do not seem to result in a durable off-treatment 
antiviral response in the majority of  HBeAg-positive 
CHB patients.
HBeAg-negative patients
Earlier studies showed consistent results that the antiviral 
response was not durable in patients who stopped NA 
therapy even if  the guideline recommendations were fol-
lowed. In a small study of  15 HBeAg-negative patients 
who stopped lamivudine after a year of  therapy, 86% of  
the patients developed virological and/or biochemical 
relapse[23]. Succeeding studies with more stringent cessa-
tion criteria showed some improvements in the durability 
of  NA-induced antiviral response, yet the results were 
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  Ref. NA n Treatment duration Cumulative relapse rate
  HBeAg-positive CHB
     Song et al[13] LMV   98 10.3 ± 3.1 mo 1 yr, 37.5%; 2 yr 49.2%
     Chien et al[14] LMV   82 16 (3-55) mo 48%1
     Dienstag et al[12] LMV   39 36.6 (4.8-45.6) mo 77%1
     Ryu et al[18] LMV   61 6 mo, 15%; 1 yr, 21%; 2 yr, 31%
     van Nunen et al[15] LMV   59 3 yr, 54%
     Byun et al[16] LMV 132 14 ± 7 mo 6 mo, 58%; 1 yr, 66%
     Yoon et al[17] LMV   95 26 mo 1 yr, 52%; 2 yr, 55.7%
     Fung et al[44] LMV   22 23 (5-91) mo 44%1
     Lee et al[19] LMV 178 26 (12-77) mo 1 yr, 15.9%; 5 yr, 30.2%
     Reijnders et al[21] Various 132 26 (16-43) mo 67%1
     Wang et al[20] LMV   82 24 (12-54) mo 1 yr, 23.4%; 2 yr, 25.0%; 4 yr, 29.4%
     Chaung et al[22] Various   39 90%1
  HBeAg-negative CHB
     Santantonio et al[23] LMV   15 52 wk 74%1
     Fung et al[24] LMV   50 2 yr 6 mo, 30%; 12 mo, 50%; 18 mo, 50%
     Chien et al[45] LMV   85 7.4 (6-12) mo 61%1
     Chan et al[46] LMV 139 24 mo 90%1
     Shouval et al[47] ETV 257 48 wk 3%1
LMV 201 48 wk 5%1
     Paik et al[25] LMV   50 24 mo 1 yr, 20.9%; 2 yr, 36.0%; 3 yr, 43.1%
     Liu et al[26] LMV   61 ≥ 24 mo 6 mo, 26.2%; 1 yr, 43.6%; 5 yr, 56.1%
     Hadziyannis et al[27] ADV   33 ≥ 4 yr 45%1
     Jeng et al[28] ETV   95 721 (395-1762) d 1 yr, 45.3%
     Kim et al[48] Various   45 6 mo, 48.9%; 1 yr, 73.3%
Table 2  Off-therapy durability of response to nucleos(t)ide analogue therapy in chronic hepatitis B patients
1Overall relapse. NA: Nucleos(t)ide analogue; CHB: Chronic hepatitis B; LMV: Lamivudine; ETV: Entecavir; ADV: Adefovir dipivoxil.
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levels during the course of  antiviral therapy may provide 
useful information regarding off-treatment response. 
Clinically, low serum levels of  HBsAg and HBV DNA 
were reported to be predictive of  spontaneous HBsAg 
seroclearance in treatment-naïve patients[32]. For HBeAg-
positive patients on NA therapy, older age, high baseline 
alanine aminotransferase and HBeAg loss were reported 
as the predictive factors for HBsAg loss[33]. Based on these 
findings, it has been suggested that monitoring of  serum 
HBsAg levels along with serum HBV DNA levels may 
guide the timing of  stopping NA therapy[34]. However, 
the clinical significance of  serum HBsAg quantitation for 
predicting HBsAg loss during antiviral therapy with NAs 
has been challenged by several studies. In a study investigat-
ing the effect of  long-term entecavir or tenofovir treatment 
on serum HBsAg levels in CHB patients, Zoutendijk et al[33]. 
reported that the predicted median time to HBsAg loss 
was 36 years for HBeAg-positive and 39 years for HBeAg-
negative patients Moreover, another study from a French 
group, based on their mathematical modeling, suggested 
that more than 50 years of  NA therapy would be required 
for the clearance of  HBsAg[35], implying that cessation of  
NA therapy would be almost impossible. Nevertheless, 
there is an increasing attention in the clinical utility of  se-
rum HBsAg quantitation, and further studies are needed 
to validate its role for monitoring the antiviral response 
and predicting the off-treatment durability.
CONCLUSION
For the minority who have achieved the ultimate goal of  
NA therapy, i.e., HBsAg loss, the treatment may be dis-
continued. However, loss of  HBsAg does not necessarily 
indicate complete eradication of  the virus as cccDNA 
persists within the infected hepatocytes, and thus there is 
still a risk of  developing HCC[36,37]. Therefore, long-term 
surveillance for HCC would be mandatory albeit success-
ful achievement of  HBsAg loss and discontinuation of  
NA therapy. 
In addition, for patients with liver cirrhosis, it would 
be beneficial to maintain than to discontinue NA therapy. 
This is supported by an increasing data that long-term 
viral suppression with NA therapy not only decreases he-
patic inflammation but also induces regression of  cirrho-
sis which may translate to improved clinical outcome[38-43].
In conclusion, while attention has been drawn to 
whether antiviral treatment with NAs can be a finite 
therapy, there is lack of  sufficient data on off-treatment 
durability of  highly potent NAs, particularly tenofovir, 
and based on the available evidences, current guidelines 
for stopping NA therapy seems to be inadequate in terms 
of  off-treatment durability. Therefore, further studies are 
required to accumulate data on off-treatment durability 
of  highly potent NAs. Furthermore, search for adequate 
predictive markers that could provide supplementary in-
formation to guide the timing of  stopping NA therapy is 
warranted. Clinical studies addressing this issue seems to 
be highly desirable in the future.
still disappointing. In a retrospective study of  50 HBeAg-
negative patients, the cumulative relapse rates at 6 mo 
was 30% and at 18 mo was 50% despite successful lami-
vudine treatment for 2 years followed by withdrawal[24]. 
Moreover, several prospective studies also demonstrated 
that off-treatment response rates were below satisfaction. 
In a long-term prospective study of  50 HBeAg-negative 
patients who stopped lamivudine after treatment for 24 
mo, the cumulative relapse rate was 43.1% at 3 years after 
withdrawal[25]. Similarly, Liu et al[26] have also reported a 
cumulative relapse rate of  56.1% at 5 years after stopping 
lamivudine treatment.
In a series of  recent studies with antiviral NAs other 
than lamivudine, the durability of  off-treatment response 
was shown to be comparable to that of  lamivudine treat-
ment. A prospective cohort study of  33 HBeAg-negative 
patients who had been treated with adefovir for 4-5 years 
and monitored for 5.5 years after cessation of  treatment 
showed an overall relapse rate of  45% during the follow-
up period[27]. Interestingly, among 18 of  33 patients who 
achieved sustained response, 13 (72%) patients showed 
HBsAg clearance. Of  note, serum HBsAg levels at the 
end of  treatment showed significant association with 
HBsAg clearance, suggesting a possible role of  HBsAg 
quantitation for predicting the antiviral response to NA 
therapy. 
A more recent study by Jeng et al[28] demonstrated off-
treatment durability of  entecavir therapy in 95 HBeAg-
negative patients using the stopping rule recommended 
by the APASL guideline. In this observational study, 
patients were treated with entecavir for a median of  721 
d, and followed up for at least 12 mo. The cumulative 
relapse rate after 1 year of  stopping entecavir treatment 
was 45.3%. 
For the patients with HBeAg-negative CHB, current 
data show that about half  of  the patients attain durable 
antiviral response after discontinuation of  NA therapy. 
This is somewhat disappointing as the off-treatment du-
rability is not satisfactory despite following the stopping 
rule recommended by the guideline. Therefore, further 
studies would be required to find adequate factors that 
could predict the best timing of  stopping the NA therapy.
HBSAG QUANTITATION AS A 
PREDICTIVE MARKER
Current guidelines for stopping NA therapy seems to 
be inadequate in terms of  off-treatment durability, with 
relapse rates of  more than 40% for both HBeAg-positive 
and HBeAg-negative patients. As a result, further studies 
are warranted to identify adequate predictive markers that 
could provide supplementary information to guide the 
timing of  stopping NA therapy.
One of  the recently proposed predictive factors for 
HBsAg loss is serum HBsAg quantitation. Since serum 
HBsAg level seems to correlate with the amount of  cova-
lently closed circular DNA (cccDNA) within the infected 
hepatocytes[29-31], serial monitoring of  serum HBsAg 
Kang W et al . Durability of nucleos(t)ide analogues therapy
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